Advertising
Showing 1 to 10 of 10 entries
  • «
  • 1
  • »

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Jan 04/22, Up 21%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with VRTX is progressing well. To remain disciplined, we recommend trailing up the stop (from $230) to $245.
Pharma & Healthcare

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Jan 04/22, Up 16.4%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with VRTX has achieved its $258 objective. To remain disciplined, we recommend covering half the position here and trailing up the stop (from $220) to $230.
Pharma & Healthcare

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Jan 04/22, Up 21.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with VRTX is progressing well. We now recommend trailing up the stop (from $200) to $220.
Pharma & Healthcare

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly We again reiterate this long known developer of treatment for cystic fibrosis as a TOP PICK. Its diversified portfolio of therapeutic drugs continues to pursue treatment in other major diseases such as Type I diabetes and muscular dystrophy. Recently reported earnings beat analyst expectations by 30% and the company maintains a ROE of 31%. We also like how the company has continued to increase cash reserves, while buying back stock. We recommend trailing up the stop (from $185) to $200, looking to achieve $258 -- upside potential over 16%. Yield 0% (Analysts’ price target is $257.41)
Pharma & Healthcare

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly This long known developer of treatment for cystic fibrosis is again reiterated as a TOP PICK. Its diversified portfolio of therapeutic drugs continues to pursue treatment in other major diseases and has recently announced success with an oral kidney treatment drug. We like how the company has continued to increase cash reserves, while paying down debt and buying back stock. We recommend trailing up the stop (from $165) to $185, looking to achieve $255 -- upside potential over 22%. Yield 0% (Analysts’ price target is $254.19)
Pharma & Healthcare

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly VRTX is a previous Top Pick that had two setbacks that caused us to recommend moving to the sidelines. However, its diversified portfolio of therapeutic drugs continues to play a leading role in the potential treatment of cystic fibrosis worldwide. It trades at 17x earning compared to peers at 43x. It has been adding cash reserves that are now estimated to exceed $8 billion. We would buy this with a stop loss at $165, looking to achieve $275 -- upside over 46%. Yield 0% (Analysts’ price target is $275.86)
Pharma & Healthcare

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Jan 19/21, Down 13.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with VRTX has triggered its stop at $200. We recommend covering the position at this time. We will look for better opportunities elsewhere.
Pharma & Healthcare

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly VRTX is a pharmaceutical company that is world renowned in its treatment for cystic fibrosis. The company is estimated to have increased its cash position by almost $2 billion, leaving it plenty in the tank to develop other life changing drugs likes ones being developed for sickle cell disease and AAT deficiency. We would buy this with a stop-loss at $200, looking to achieve $290 -- over 25% upside potential. Yield 0% (Analysts’ price target is $289.66)
Pharma & Healthcare
PAST TOP PICK
(A Top Pick Nov 14/19, Up 16%) This shot up from its base around $175 starting last October. No longer owns it. Pharma is fairly predictable, buy may be kicked around by US politicians during the campaign. He suggests entering the pharma space now.
Pharma & Healthcare
TOP PICK
They specialize in serious diseases. It is volatile. You could just own the XBB-T. He thinks our life span is going to expand significantly and these guys are going to be part of it. (Analysts’ price target is $226.45)
Pharma & Healthcare
Showing 1 to 10 of 10 entries
  • «
  • 1
  • »

Vertex Pharmaceuticals Inc.(VRTX-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 3

Stockchase rating for Vertex Pharmaceuticals Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Vertex Pharmaceuticals Inc.(VRTX-Q) Frequently Asked Questions

What is Vertex Pharmaceuticals Inc. stock symbol?

Vertex Pharmaceuticals Inc. is a American stock, trading under the symbol VRTX-Q on the NASDAQ (VRTX). It is usually referred to as NASDAQ:VRTX or VRTX-Q

Is Vertex Pharmaceuticals Inc. a buy or a sell?

In the last year, 3 stock analysts published opinions about VRTX-Q. 3 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Vertex Pharmaceuticals Inc..

Is Vertex Pharmaceuticals Inc. a good investment or a top pick?

Vertex Pharmaceuticals Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Vertex Pharmaceuticals Inc..

Why is Vertex Pharmaceuticals Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Vertex Pharmaceuticals Inc. worth watching?

3 stock analysts on Stockchase covered Vertex Pharmaceuticals Inc. In the last year. It is a trending stock that is worth watching.

What is Vertex Pharmaceuticals Inc. stock price?

On 2022-08-10, Vertex Pharmaceuticals Inc. (VRTX-Q) stock closed at a price of $295.77.